Format

Send to

Choose Destination
See comment in PubMed Commons below

Dystonia/Parkinsonism, Hypermanganesemia, Polycythemia, and Chronic Liver Disease.

Source

GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017.
2012 Aug 30 [updated 2017 Feb 9].

Author information

1
Genetics and Genomic Medicine, UCL GOS Institute of Child Health, London, United Kingdom
2
Departments of Neurology and Pediatrics, University of Washington, Seattle Children’s Hospital, Seattle, Washington

Excerpt

CLINICAL CHARACTERISTICS:

The disorder dystonia/parkinsonism, hypermanganesemia, polycythemia, and chronic liver disease is characterized by the following: A movement disorder resulting from manganese accumulation in the basal ganglia. Whole-blood manganese concentrations that often exceed 2000 nmol/L (normal: <320 nmol/L). Polycythemia. Hepatomegaly with variable hepatic fibrosis/cirrhosis. Neurologic findings can manifest: in childhood (ages 2-15 years) as four-limb dystonia, leading to a characteristic high-stepping gait (“cock-walk gait”), dysarthria, fine tremor, and bradykinesia or on occasion spastic paraplegia; or in adulthood as parkinsonism (shuffling gait, rigidity, bradykinesia, hypomimia, and monotone speech) unresponsive to L-dopa treatment. Hepatic failure, secondary complications of cirrhosis, and the neurologic disorder shorten life expectancy.

DIAGNOSIS/TESTING:

The diagnosis is suggested by characteristic clinical and brain MRI findings, elevated whole-blood concentration of manganese, and polycythemia. It is confirmed by identification of biallelic pathogenic variants in SLC30A10.

MANAGEMENT:

Treatment of manifestations: Regular chelation therapy with intravenous disodium calcium edetate improves blood manganese levels and neurologic findings and causes signs of liver disease to disappear. In addition, supplementation with oral iron therapy (despite normal serum iron levels) can reduce blood manganese levels and resolve polycythemia. Liver transplantation should be considered in individuals with end-stage liver disease, although it has not yet been attempted in this disorder. Prevention of primary manifestations: Chelation therapy and iron supplementation may prevent primary disease manifestations in affected asymptomatic sibs. Prevention of secondary complications: Early initiation of physiotherapy and orthopedic management aims to prevent contractures and maintain ambulation. Symptomatic treatment with antispasticity medications (including baclofen and botulinum toxin) and levodopa may be attempted. Swallowing evaluation and regular dietary assessments are indicated to assure adequate nutrition. In order to prevent aspiration pneumonia gastric feeding tube and/or tracheostomy may be required. The potential for complications from chelation therapy and/or iron supplementation can be lessened by careful surveillance Agents/circumstances to avoid: Foods very high in manganese: cloves; saffron; nuts; mussels; dark chocolate; and pumpkin, sesame, and sunflower seeds Evaluation of relatives at risk: Because chelation therapy and iron supplementation could prevent primary disease manifestations in affected asymptomatic individuals, it is recommended that at-risk sibs of a proband be evaluated either by molecular genetic testing (if the pathogenic variants in the family are known) or by periodic monitoring of whole-blood manganese concentration and hemoglobin.

GENETIC COUNSELING:

Dystonia/parkinsonism, hypermanganesemia, polycythemia, and chronic liver disease is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and prenatal diagnosis for pregnancies at increased risk are possible if the SLC30A10 pathogenic variants in the family are known.

Copyright © 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Support Center